16α-methoxy-5α-androstan-17-one | 112859-80-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 16α-methoxy-5α-androstan-17-one
• 英文别名: (5R,8R,9S,10S,13S,14S,16R)-16-methoxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
• CAS: 112859-80-0
• 化学式: C₂₀H₃₂O₂
• 分子量: 304.473
• InChiKey: BVKFNOSIDFORNM-DGNOAVAJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  16α-methoxy-5α-androstan-17-one 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以44%的产率得到16α-methoxy-5α-androstan-17α-ol
  参考文献：
  名称：

  Gas chromatography–mass spectrometric analysis of oxidative reactions of [19,19-2H2]19-hydroxy-3-deoxy androgens by placental aromatase

  摘要：

  Aromatase is a cytochrome P-450 enzyme complex that catalyzes the conversion of androst-4-ene-3,17-dione (AD) to estrone through three sequential oxidations of the 19-methyl group. 3-DeoxyAD (1) and its 5-ene isomer 4 are potent and good competitive aromatase inhibitors, which are converted by aromatase to the aldehyde derivatives 3 and 6, respectively, through 19-hydroxy intermediates 2 and 5, respectively. To study the deuterium isotope effect on the conversions of 19-ols 2 and 5 into the corresponding 19-als 3 and 6, we initially synthesized [19,19-H-2(2)]19-ols 2 and 5 starting from the corresponding non-labeled 19-als 3 and 6 through (NaBH4)-H-2 reduction of the 19-aldehyde group, followed by oxidation with pyridinium dichromate, and a subsequent NaB2H4 reduction. Approximately 1:1 mixtures of non-labeled (d(0)) and deuterated (d(2)) 19-ols 2 and 5 were separately incubated with human placental microsomes in the presence of NADPH under an air atmosphere, and deuterium contents of the recovered substrates and the 19-aldehyde products were determined by gas chromatography-mass spectrometry. In each experiment, the ratio of d(0) to d(2) of the recovered substrate along with that of do to all of the product were identical to the d(0) to d(2) ratio of the employed substrate irrespective of the incubation time, indicating that the 19-oxygenations of the 3-deoxy steroids 2 and 5 proceeded without a detectable isotope effect, as seen in the aromatization sequence of the natural substrate AD. (c) 2005 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2005.04.009
• 作为产物：
  描述：

  16α-hydroxy-5α-androstan-17-one 、 碘甲烷 在 silver(l) oxide 作用下， 反应 10.0h， 以60%的产率得到16α-methoxy-5α-androstan-17-one
  参考文献：
  名称：

  Gas chromatography–mass spectrometric analysis of oxidative reactions of [19,19-2H2]19-hydroxy-3-deoxy androgens by placental aromatase

  摘要：

  Aromatase is a cytochrome P-450 enzyme complex that catalyzes the conversion of androst-4-ene-3,17-dione (AD) to estrone through three sequential oxidations of the 19-methyl group. 3-DeoxyAD (1) and its 5-ene isomer 4 are potent and good competitive aromatase inhibitors, which are converted by aromatase to the aldehyde derivatives 3 and 6, respectively, through 19-hydroxy intermediates 2 and 5, respectively. To study the deuterium isotope effect on the conversions of 19-ols 2 and 5 into the corresponding 19-als 3 and 6, we initially synthesized [19,19-H-2(2)]19-ols 2 and 5 starting from the corresponding non-labeled 19-als 3 and 6 through (NaBH4)-H-2 reduction of the 19-aldehyde group, followed by oxidation with pyridinium dichromate, and a subsequent NaB2H4 reduction. Approximately 1:1 mixtures of non-labeled (d(0)) and deuterated (d(2)) 19-ols 2 and 5 were separately incubated with human placental microsomes in the presence of NADPH under an air atmosphere, and deuterium contents of the recovered substrates and the 19-aldehyde products were determined by gas chromatography-mass spectrometry. In each experiment, the ratio of d(0) to d(2) of the recovered substrate along with that of do to all of the product were identical to the d(0) to d(2) ratio of the employed substrate irrespective of the incubation time, indicating that the 19-oxygenations of the 3-deoxy steroids 2 and 5 proceeded without a detectable isotope effect, as seen in the aromatization sequence of the natural substrate AD. (c) 2005 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2005.04.009

文献信息

• Compounds useful for treating hypertriglyceridemia
  申请人：——

  公开号：US20040019026A1

  公开（公告）日：2004-01-29

  The present invention is directed to a method for treating a patient having hypertriglyceridemia comprising administering thereto a compound of the formula: 1

  本发明涉及一种治疗高甘油三酯血症患者的方法，包括向其投药式为1的化合物。
• COMPOUNDS USEFUL FOR TREATING HYPERTRIGLYCERIDEMIA
  申请人：Aeson Therapeutics Inc.

  公开号：EP1351971A2

  公开（公告）日：2003-10-15
• [EN] COMPOUNDS USEFUL FOR TREATING HYPERTRIGLYCERIDEMIA<br/>[FR] COMPOSES SERVANT A TRAITER L'HYPERTRIGLYCERIDEMIE
  申请人：AESON THERAPEUTICS INC

  公开号：WO2002028880A2

  公开（公告）日：2002-04-11

  The present invention is directed to a method for treating a patient having hypertriglyceridemia comprising administering thereto a compound of the formula: I